Abnormal Glucuronidation of Zomepirac in Patients with Cirrhosis of the Liver
Felix Witassek, Johannes Bircher, Philipp Huguenin, Rudolf Preisig – 1 January 1983 – The disposition of zomepirac was investigated in 18 patients with various liver diseases and in 10 healthy normal subjects in order to further test the hypothesis that glucuronidation of drugs may be spared in liver disease. Severity of the liver disease was assessed by the galactose elimination capacity. Following oral administration of zomepirac (200 mg), plasma and urinary drug concentrations were measured by high‐pressure liquid chromatography. Urine was assayed before and after alkaline hydrolysis.